CL2018003292A1 - Kit que comprende un anticuerpo anti-cd38 y lenalidomida util para tratar mieloma múltiple (divisional de solicitud 1558-2015). - Google Patents

Kit que comprende un anticuerpo anti-cd38 y lenalidomida util para tratar mieloma múltiple (divisional de solicitud 1558-2015).

Info

Publication number
CL2018003292A1
CL2018003292A1 CL2018003292A CL2018003292A CL2018003292A1 CL 2018003292 A1 CL2018003292 A1 CL 2018003292A1 CL 2018003292 A CL2018003292 A CL 2018003292A CL 2018003292 A CL2018003292 A CL 2018003292A CL 2018003292 A1 CL2018003292 A1 CL 2018003292A1
Authority
CL
Chile
Prior art keywords
lenalidomide
multiple myeloma
antibody
kit
useful
Prior art date
Application number
CL2018003292A
Other languages
English (en)
Inventor
Byron C Hann
Iii Thomas G Martin
Blake T Aftab
Blake Tomkinson
Original Assignee
Univ California
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Sanofi Sa filed Critical Univ California
Publication of CL2018003292A1 publication Critical patent/CL2018003292A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES Y KITS QUE COMPRENDEN ANTICUERPOS ANTI-CD38 Y COMPUESTOS DE LENALIDOMIDA ÚTILES PARA TRATAR CÁNCERES, TALES COMO MIELOMA MÚLTIPLE, EN SUJETOS.
CL2018003292A 2012-12-07 2018-11-20 Kit que comprende un anticuerpo anti-cd38 y lenalidomida util para tratar mieloma múltiple (divisional de solicitud 1558-2015). CL2018003292A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US201361808372P 2013-04-04 2013-04-04

Publications (1)

Publication Number Publication Date
CL2018003292A1 true CL2018003292A1 (es) 2019-02-01

Family

ID=50884019

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015001558A CL2015001558A1 (es) 2012-12-07 2015-06-05 Composiciones que contienen anticuerpos anti-cd38 y lenalidomida
CL2018003292A CL2018003292A1 (es) 2012-12-07 2018-11-20 Kit que comprende un anticuerpo anti-cd38 y lenalidomida util para tratar mieloma múltiple (divisional de solicitud 1558-2015).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015001558A CL2015001558A1 (es) 2012-12-07 2015-06-05 Composiciones que contienen anticuerpos anti-cd38 y lenalidomida

Country Status (31)

Country Link
EP (2) EP3597191A1 (es)
JP (2) JP6499971B2 (es)
KR (2) KR20200143503A (es)
CN (1) CN105263520B (es)
AR (1) AR093844A1 (es)
AU (2) AU2013355064B2 (es)
BR (1) BR112015012987A2 (es)
CA (1) CA2893946A1 (es)
CL (2) CL2015001558A1 (es)
CY (2) CY1122478T1 (es)
DK (1) DK2928495T3 (es)
ES (1) ES2731548T3 (es)
HR (1) HRP20191034T1 (es)
HU (3) HUE044142T2 (es)
IL (2) IL239234B (es)
LT (2) LT2928495T (es)
LU (1) LUC00187I2 (es)
MX (2) MX366296B (es)
MY (1) MY191601A (es)
NL (1) NL301079I2 (es)
NZ (1) NZ709215A (es)
PH (1) PH12015501263A1 (es)
PL (1) PL2928495T3 (es)
PT (1) PT2928495T (es)
RS (1) RS58829B1 (es)
RU (1) RU2698911C2 (es)
SG (3) SG11201504315WA (es)
SI (1) SI2928495T1 (es)
TW (2) TWI670062B (es)
UA (1) UA118255C2 (es)
WO (1) WO2014089416A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
US12371506B2 (en) 2018-01-12 2025-07-29 Takeda Pharmaceutical Company Limited Subcutaneous administration of anti-CD38 antibodies
JP7581052B2 (ja) * 2018-04-13 2024-11-12 サムヤン ホールディングス コーポレイション レナリドミドの経口用コーティング錠剤組成物
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
WO2019199132A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 다양한 용량의 레날리도마이드의 경구용 정제 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
SG11202011306TA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
AU2019351811B2 (en) * 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
JP7687956B2 (ja) * 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN113993543B (zh) * 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
AU2020376305A1 (en) * 2019-10-31 2022-05-12 Incyte Corporation Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
TW202606756A (zh) 2019-12-05 2026-02-16 美商賽諾菲阿凡提斯美國有限責任公司 用於皮下投予之抗cd38抗體的調配物
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR101217385B1 (ko) * 2004-12-21 2012-12-31 닛뽄 가야쿠 가부시키가이샤 에폭시 수지, 에폭시 수지 조성물 및 그의 경화물
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
NZ607473A (en) 2010-09-27 2014-11-28 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
MY191601A (en) 2022-07-01
PL2928495T3 (pl) 2019-09-30
KR20150091165A (ko) 2015-08-07
MX2015007189A (es) 2016-03-21
AU2013355064B2 (en) 2018-05-24
EP3597191A1 (en) 2020-01-22
TW201919699A (zh) 2019-06-01
IL282542A (en) 2021-06-30
ES2731548T3 (es) 2019-11-15
EP2928495B1 (en) 2019-03-27
CN105263520B (zh) 2020-03-13
JP6499971B2 (ja) 2019-04-10
CL2015001558A1 (es) 2015-10-02
HUE044142T2 (hu) 2019-09-30
KR20200143503A (ko) 2020-12-23
TWI670062B (zh) 2019-09-01
LTPA2020537I1 (lt) 2020-12-28
RU2015127089A (ru) 2017-01-13
HUS2000051I1 (hu) 2020-12-28
CY2020040I2 (el) 2021-05-05
HUS2000050I1 (hu) 2020-12-28
KR102193045B1 (ko) 2020-12-18
CY1122478T1 (el) 2021-01-27
CY2020040I1 (el) 2021-03-12
RU2698911C2 (ru) 2019-09-02
IL239234B (en) 2021-05-31
LUC00187I2 (es) 2024-07-01
AR093844A1 (es) 2015-06-24
AU2013355064A1 (en) 2015-07-09
CN105263520A (zh) 2016-01-20
DK2928495T3 (da) 2019-06-24
UA118255C2 (uk) 2018-12-26
LTC2928495I2 (lt) 2024-11-25
PT2928495T (pt) 2019-07-04
NZ709215A (en) 2020-08-28
SG11201504315WA (en) 2015-07-30
HK1215536A1 (en) 2016-09-02
IL239234A0 (en) 2015-07-30
HRP20191034T1 (hr) 2019-08-23
EP2928495A4 (en) 2016-05-11
MX366296B (es) 2019-07-04
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
SI2928495T1 (sl) 2019-07-31
JP2016506388A (ja) 2016-03-03
CA2893946A1 (en) 2014-06-12
EP2928495A1 (en) 2015-10-14
AU2018211258A1 (en) 2018-08-16
PH12015501263A1 (en) 2015-08-17
LT2928495T (lt) 2019-07-10
JP2019070020A (ja) 2019-05-09
WO2014089416A1 (en) 2014-06-12
SG10201704536PA (en) 2017-07-28
SG10201913783PA (en) 2020-03-30
MX2019008065A (es) 2019-09-23
RS58829B1 (sr) 2019-07-31
BR112015012987A2 (pt) 2017-09-12

Similar Documents

Publication Publication Date Title
MX2015007189A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
MX373308B (es) Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib.
AR089178A1 (es) Anticuerpos anti-il-36r
SA521430032B1 (ar) Vista أجسام مضادة لـ وأجزاء منها
UY40672A (es) “ANTICUERPOS AISLADOS BIESPECÍFICOS GPRC5D x CD3 Y COMPOSICIONES QUÍMICAS QUE LOS CONTIENEN”
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
AR090923A1 (es) Anticuerpos anti-il-23
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
EA201400875A1 (ru) Антитела к cd47 и способы их применения
MX386342B (es) Móleculas de unión a her2 y cd3 biespecíficas.
UA114901C2 (uk) Інгібітори асс та їх застосування
PH12017500864A1 (en) Anti-notch1 antibodies
EA201690443A1 (ru) Биспецифические моновалентные диатела, которые способны связываться с cd123 и cd3, и их применения
MX369148B (es) Agentes de unión kir3dl2.
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
EA201400447A1 (ru) АНТИТЕЛА К CD1d
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
AR123070A2 (es) Anticuerpos anti-il-23
TN2014000207A1 (en) Anti il-36r antibodies
EA201990353A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ СПОСОБНОСТЬЮ НЕЙТРАЛИЗОВАТЬ ГЛАВНЫЕ ЭКЗОТОКСИНЫ TcdA И TcdB Clostridium difficile
CR20150259A (es) Anticuerpos egfr/c-met biespecíficos
CO6690756A2 (es) Nuevos moduladores de trpv3
TN2013000186A1 (en) Anti-il-23 antibodies